Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594613 | 0.77 | LMNA (0.35) | LMNAMAPT | |
| Phosphoric Acid SCHEMBL17537058 | 0.71 | FGFR1 (0.36) | LMNAMAPT | |
| SCHEMBL4307802 | 0.65 | LMNA (0.46) | LMNAMAPT | |
| SCHEMBL12741775 | 0.62 | ALB (0.36) | — | |
| SCHEMBL1174410 | 0.57 | BIRC5 (0.42) | LMNAMAPT | |
| SCHEMBL18244672 | 0.57 | CDK2 (0.46) | — | |
| SCHEMBL21227587 | 0.55 | MAPT (0.37) | LMNAMAPT | |
| SCHEMBL8054416 | 0.55 | LMNA (0.43) | LMNAMAPT | |
| SCHEMBL15412261 | 0.55 | LMNA (0.32) | LMNAMAPT | |
| SCHEMBL5600749 | 0.54 | LMNA (0.37) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987233-A | Pharmaceutical composition for treating classical hodgkin lymphoma and application thereof | 武汉科技大学 | 2024-11-22 | — | — | CN | claimed |
| WO-2022173711-A9 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022173711-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220249534-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | THE GENERAL HOSPITAL CORPORATION | 2022-08-11 | — | — | US | claimed |
| CN-110051846-A | A kind of antineoplastic pharmaceutical compositions and its application based on humoral immunity blocking | 中山大学 | 2019-07-26 | — | — | CN | claimed |
| CN-109999038-A | A kind of antineoplastic pharmaceutical compositions and its application based on blocking macrophage effect | 中山大学 | 2019-07-12 | — | — | CN | claimed |
| EP-3207932-A1 | DNA METHYLTRANSFERASE INHIBITORS FOR RETT SYNDROME THERAPY | Universität Stuttgart (DE) | 2017-08-23 | — | — | EP | claimed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | AVIGAN DAVID (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250295686-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-118987233-A | Pharmaceutical composition for treating classical hodgkin lymphoma and application thereof | 武汉科技大学 | 2024-11-22 | — | — | CN | disclosed |
| EP-4419209-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-9150520-B2 | Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one | REXAHN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150167004-A1 | OLIGONUCLEOTIDE INHIBITORS OF DNA METHYLTRANSFERASES AND THEIR USE IN TREATING DISEASES | METHEOR THERAPEUTICS CORPORATION | 2015-06-18 | — | — | US | disclosed |
| EP-2869852-A2 | OLIGONUCLEOTIDE INHIBITORS OF DNA METHYLTRANSFERASES AND THEIR USE IN TREATING DISEASES | Metheor Therapeutics Corporation (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20150038548-A1 | OLIGONUCLEOTIDE INHIBITORS OF DNA METHYLTRANSFERASES AND THEIR USE IN TREATING DISEASES | METHEOR THERAPEUTICS CORPORATION | 2015-02-05 | — | — | US | disclosed |
| WO-2014145807-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R, 5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275537-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014011573-A2 | OLIGONUCLEOTIDE INHIBITORS OF DNA METHYLTRANSFERASES AND THEIR USE IN TREATING DISEASES | METHEOR THERAPEUTICS CORPORATION (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275537-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | RXFP4, RXFP1, NPY4R | MEN1 1273/4885KMT2A 1861/4885LMNA 3265/4885 |
| US-20250319183-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MCL1, BCL2, BCL3 | MEN1 2632/4885KMT2A 2681/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.